Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Our Vision: A World Free of Pain

Grünenthal Stories

Grünenthal Annual Report 2023/24 (Grünenthal Scientific Body & Grünenthal Report Cover Image)

Annual Report 2023/24

4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.

Our most recent report shares information about our company’s strategy, highlight projects and financial performance.

... Check out the Grünenthal Report.
Full Years Results 2023

Grünenthal 2023 full-year results

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over prior year. The adjusted EBITDA was €427 million, a decrease of three percent vs. prior year due to increased investments in growth through Research & Development (R&D), acquisitions, and modernising production facilities. Grünenthal has more than tripled its adjusted EBITDA since 2017. Grünenthal’s R&D pipeline has progressed substantially with its Phase III development projects of RTX and Qutenza™.
... Read the 2023 full-year results press release
Grünenthal Responsibility

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.
... Check out our latest Responsibility Report.

Our commitment to the PSCI

Grünenthal is a member of the Pharmaceutical Supply Chain Initiative (PSCI) ( This global movement is driving positive change in our industry through collaboration to promote more responsible and sustainable practices along the entire value chain. It brings together pharma companies, suppliers and other stakeholders with the shared mission of promoting progress. By working together, we aim to ensure access to safe and reliable medicines for patients worldwide.

... Find more information about Grünenthal’s commitment to responsible sourcing here.

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to resiniferatoxin for pain associated with knee osteoarthritis (OA). The investigational, non-opioid medicine is currently in Phase III clinical development.

Knee OA affects more than 360 million people worldwide. Patients often experience severe pain, and many are impacted in their daily activities. If approved, resiniferatoxin could become a meaningful treatment option providing long-lasting pain relief and functional improvement of the affected joint.

Learn more about our asset and how it may address one of the most common and severe symptoms in knee OA

... Download PR FDA Breakthrough Therapy Designation for Grünenthal’s resiniferatoxin
Job Portal - Tout Primary 1800x759px


Working at Grünenthal means experiencing the impact you can have on the results we achieve and the lives of the patients we serve.

Join forces.

Make an impact.

Innovate for a world free of pain.

... Visit our careers website